Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
NEW YORK – Nippon Shinyaku and Atsena Therapeutics on Wednesday said they inked an exclusive license agreement to commercialize ATSN-101, Atsena's investigational gene therapy for GUCY2D-mutated Leber ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback